Comparing DocGo (NASDAQ:DCGO) and GeneDx (NASDAQ:WGS)

GeneDx (NASDAQ:WGS) and DocGo (NASDAQ:DCGO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current recommendations for GeneDx and DocGo, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	1	7	0	2.67
DocGo	1	2	2	0	2.20

GeneDx presently has a consensus target price of $90.86, indicating a potential upside of 31.56%. DocGo has a consensus target price of $2.17, indicating a potential upside of 777.55%. Given DocGo’s higher probable upside, analysts plainly believe DocGo is more favorable than GeneDx.

Insider & Institutional Ownership

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 5.1% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

GeneDx has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, DocGo has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Earnings and Valuation

This table compares GeneDx and DocGo”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54 million	4.82	-$21.02 million	($3.64)	-18.97
DocGo	$322.20 million	0.08	-$182.40 million	($1.96)	-0.13

GeneDx has higher revenue and earnings than DocGo. GeneDx is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GeneDx and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
DocGo	-65.29%	-40.42%	-24.81%

Summary

GeneDx beats DocGo on 11 of the 13 factors compared between the two stocks.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.